Arterial stiffness progression in metabolic dysfunction-associated fatty liver disease subtypes: A prospective cohort study

被引:1
|
作者
Liu, Lei [1 ]
Zhou, Yufu
Deng, Shuwen [1 ]
Yuan, Ting [1 ]
Yang, Saiqi [1 ]
Zhu, Xiaoling [1 ]
Wang, Changfa [2 ]
Wang, Yaqin [1 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Hlth Management Ctr, Dept Gastroenterol, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp 3, Gen Surg Dept, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China
关键词
Arterial stiffness; Brachial ankle pulse wave velocity (baPWV); Metabolic dysfunction-associated fatty liver (MAFLD); Diabetes; ASIA-PACIFIC REGION; CARDIOVASCULAR-DISEASE; RISK-FACTORS;
D O I
10.1016/j.numecd.2024.03.030
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: We aimed to investigate the correlation and to explore which MAFLD subtypes have the greatest influence on progression of arterial stiffness risk. Methods and results: Using data from a health examination-based cohort, a total of 12,129 participants who underwent two repeated health examinations that included brachial-ankle pulse wave velocity (baPWV) from 2012 to 2020 were enrolled. Participants were separated into non-MAFLD, overweight/obese (OW-MAFLD), lean/normal weight (lean-MAFLD) and diabetes (DM-MAFLD) groups. Among the participants with a median follow-up of 2.17 years, 4511 (37.2%) participants had MAFLD at baseline, among which 3954 (87.7%), 123 (2.7%), and 434 (9.6%) were OW-, lean- and DM-MAFLD, respectively. Analyses using linear regression models confirmed that compared with the non-MAFLD group, the elevated baPWV change rates (cm/s/ year) were 12.87 (8.81-16.94), 25.33 (7.84-42.83) and 38.49 (27.88-49.10) in OW, lean and DM -MAFLD, respectively, while the increased change proportions (%) were 1.53 (1.10-1.95), 3.56 (1.72-5.40) and 3.94 (2.82-5.05), respectively. Similar patterns were observed when these two baPWV parameters were transformed in the form of the greatest increase using Cox proportional hazards model analyses. Furthermore, the risk of arterial stiffness progression across MAFLD subtypes presented a significant, gradient, inverse relationship in the order of DM-, lean-, OW with metabolic abnormalities (MA)-, and OW without MA-MAFLD. Conclusion: MAFLD, especially DM-MAFLD and lean-MAFLD, was significantly associated with arterial stiffness progression, providing evidence that stratification screening and surveillance strategies for CVD risk have important clinical implications. (c) 2024 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1890 / 1900
页数:11
相关论文
共 50 条
  • [41] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [42] METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IS ASSOCIATED WITH INCREASED RISK OF LIVER-RELATED COMPLICATIONS: A NATIONWIDE COHORT STUDY
    Shin, Hyunjae
    Park, Min Kyung
    Moon, Hye-Sung
    Chung, Sung Won
    Ko, Yunmi
    Park, Youngsu
    Park, Jeayeon
    Hur, Moon Haeng
    Bin Lee, Yun
    Cho, Eun Ju
    Lee, Jeong-Hoon
    Yu, Su Jong
    Yoon, Jung-Hwan
    Kim, Yoon Jun
    HEPATOLOGY, 2023, 78 : S1012 - S1013
  • [43] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Ting-Yao Wang
    Rui-Fang Wang
    Zhi-Ying Bu
    Giovanni Targher
    Christopher D. Byrne
    Dan-Qin Sun
    Ming-Hua Zheng
    Nature Reviews Nephrology, 2022, 18 : 259 - 268
  • [44] The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease
    Barrera, Francisco
    Uribe, Javier
    Olvares, Nixa
    Huerta, Paula
    Cabrera, Daniel
    Romero-Gomez, Manuel
    ANNALS OF HEPATOLOGY, 2024, 29 (04)
  • [45] Association of metabolic dysfunction-associated fatty liver disease with kidney disease
    Wang, Ting-Yao
    Wang, Rui-Fang
    Bu, Zhi-Ying
    Targher, Giovanni
    Byrne, Christopher D.
    Sun, Dan-Qin
    Zheng, Ming-Hua
    NATURE REVIEWS NEPHROLOGY, 2022, 18 (04) : 259 - 268
  • [46] The Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Peripheral Arterial Disease in the Chinese Population
    Song, Xiao-Hui
    Liu, Bo
    Lei, Fang
    Liu, Ye-Mao
    Zhang, Xingyuan
    Chen, Ze
    Zhang, Peng
    Zhang, Xiao-Jing
    She, Zhi-Gang
    Cai, Jingjing
    Wang, Jin-Hua
    Li, Hongliang
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 373 - 384
  • [47] Gastric Bypass Resolves Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Low-BMI Patients A Prospective Cohort Study
    Billeter, Adrian T.
    Scheurlen, Katharina M.
    Israel, Barbara
    Straub, Beate K.
    Schirmacher, Peter
    Kopf, Stefan
    Nawroth, Peter P.
    Mueller-Stich, Beat P.
    ANNALS OF SURGERY, 2022, 276 (05) : 814 - 821
  • [48] Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study
    Peng, Yu
    Wang, Peng
    Liu, Fubin
    Wang, Xixuan
    Si, Changyu
    Gong, Jianxiao
    Zhou, Huijun
    Gu, Jiale
    Qin, Ailing
    Song, Weijie
    Song, Fangfang
    DIABETES OBESITY & METABOLISM, 2025, 27 (04): : 1940 - 1949
  • [49] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    Han, A. Lum
    DIABETOLOGY & METABOLIC SYNDROME, 2022, 14 (01):
  • [50] Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
    A Lum Han
    Diabetology & Metabolic Syndrome, 14